Provectus Biopharmaceuticals, Inc. Receives Patent from USPTO Related to Rose Bengal Analogs

KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Biopharmaceuticals, Inc. (NYSEMKT:PVCT, www.provectusbio.com),
a clinical-stage oncology and dermatology biopharmaceutical company
(“Provectus” or the “Company”) today announced that it has received a
U.S. patent covering additional aspects of its process for synthesizing
halogenated xanthenes, the family of compound to which rose bengal
belongs. The patent covers use of certain halogenated xanthenes in
pharmaceutical compositions and as medicaments.
Eric Wachter, CTO of Provectus, noted, “U.S. Patent No. 9,422,260 covers
claims that we announced in mid-July had been allowed by the U.S. Patent
and Trademark Office. It covers subject matter included in the original,
‘parent’ case that led to issuance of U.S. Patent 8,530,675 in September
2013, covering our novel process for synthesizing rose bengal and
related analogs. This ‘daughter’ patent extends protection to use of a
wide range of those analogs in or as therapeutic products, and provides
complementary protection to that afforded by the parent patent.”
Wachter added, “The daughter patent provides a significant potential
commercial lifetime for these analogs. Along with U.S. Patent No.
9,273,022, issued earlier this year and also derived from the original
parent case, the new patent expands our ability to control the supply
chain for rose bengal and related analogs for use in PV-10, PH-10 and
possible successor products.”
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals is investigating new therapies for the
treatment of skin cancer, liver cancer and breast cancer. Provectus’
investigational oncology drug, PV-10, is an ablative immunotherapy under
investigation in solid tumor cancers. The Company has received orphan
drug designations from the FDA for its melanoma and hepatocellular
carcinoma indications. PH-10, its topical investigational drug for
dermatology, is undergoing clinical testing for psoriasis and atopic
dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy
for metastatic melanoma, and of PH-10 as a topical treatment for atopic
dermatitis and psoriasis. Information about these and the Company’s
other clinical trials can be found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus, please visit the Company’s
website at www.provectusbio.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains “forward-looking
statements” as defined under U.S. federal securities laws. These
statements reflect management’s current knowledge, assumptions, beliefs,
estimates, and expectations and express management’s current views of
future performance, results, and trends and may be identified by their
use of terms such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and
other similar terms. Forward-looking statements are subject to a number
of risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking
statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements
include those discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2015) and the following:

• our determination, based on guidance from the FDA, whether to proceed
  with or without a partner with the fully enrolled phase 3 trial of
  PV-10 to treat locally advanced cutaneous melanoma and the costs
  associated with such a trial if it is necessary to complete (versus
  interim data alone);
• our determination whether to license PV-10, our investigational drug
  product for melanoma and other solid tumors such as cancers of the
  liver, if such licensure is appropriate considering the timing and
  structure of such a license, or to commercialize PV-10 on our own to
  treat melanoma and other solid tumors such as cancers of the liver;
• our ability to license PH-10, our investigational drug product for
  dermatology, on the basis of our phase 2 atopic dermatitis and
  psoriasis results, which are in the process of being further developed
  in conjunction with mechanism of action studies; and
• our ability to raise additional capital if we determine to
  commercialize PV-10 and/or PH-10 on our own, although our expectation
  is to be acquired by a prospective pharmaceutical or biotech concern
  prior to commercialization.